In this regard, CCA exhibits particularly high FGFR fusion prevalence and therapeutic potential, and importantly, FGFR2 is emerging as a significant fusion partner, along with its associate protein Shootin1 (Krook et al., 2020; Li et al., 2020; Deng et al., 2023). This evidence concerns the gene FGFR2 and cholangiocarcinoma.